Analysts Expect Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.56 Earnings Per Share

Wall Street analysts expect that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post earnings per share of ($0.56) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.65). Rhythm Pharmaceuticals posted earnings per share of ($0.41) in the same quarter last year, which indicates a negative year over year growth rate of 36.6%. The company is scheduled to report its next quarterly earnings report on Monday, March 11th.

On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.29) to ($2.10). For the next financial year, analysts expect that the firm will report earnings of ($2.56) per share, with EPS estimates ranging from ($3.66) to ($1.93). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Rhythm Pharmaceuticals.

Several research firms recently issued reports on RYTM. BidaskClub upgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Stifel Nicolaus reiterated a “hold” rating and set a $36.00 price target on shares of Rhythm Pharmaceuticals in a research report on Sunday, November 11th. ValuEngine upgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. Needham & Company LLC set a $42.00 price target on shares of Rhythm Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 14th. Finally, Zacks Investment Research lowered shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $38.25.

In related news, CEO Keith Michael Gottesdiener sold 15,779 shares of the stock in a transaction that occurred on Wednesday, January 23rd. The shares were sold at an average price of $30.05, for a total transaction of $474,158.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 26,756 shares of company stock worth $803,570 in the last quarter. 4.93% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of RYTM. Geode Capital Management LLC boosted its position in Rhythm Pharmaceuticals by 30.2% in the fourth quarter. Geode Capital Management LLC now owns 233,894 shares of the company’s stock valued at $6,287,000 after buying an additional 54,247 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $1,447,000. Great West Life Assurance Co. Can acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $68,000. Emory University acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $2,225,000. Finally, Citigroup Inc. boosted its position in Rhythm Pharmaceuticals by 147.5% in the fourth quarter. Citigroup Inc. now owns 67,903 shares of the company’s stock valued at $1,825,000 after buying an additional 40,469 shares in the last quarter. Institutional investors and hedge funds own 90.56% of the company’s stock.

Shares of NASDAQ RYTM traded up $0.07 during trading hours on Wednesday, hitting $29.78. 36,400 shares of the stock were exchanged, compared to its average volume of 88,540. The firm has a market capitalization of $975.54 million, a price-to-earnings ratio of -10.52 and a beta of 1.41. Rhythm Pharmaceuticals has a 1-year low of $16.80 and a 1-year high of $37.23.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Recommended Story: Bond

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit